BRPI0920749A8 - Proteínas de ligação de antagonista multialvo cd86 - Google Patents

Proteínas de ligação de antagonista multialvo cd86

Info

Publication number
BRPI0920749A8
BRPI0920749A8 BRPI0920749A BRPI0920749A BRPI0920749A8 BR PI0920749 A8 BRPI0920749 A8 BR PI0920749A8 BR PI0920749 A BRPI0920749 A BR PI0920749A BR PI0920749 A BRPI0920749 A BR PI0920749A BR PI0920749 A8 BRPI0920749 A8 BR PI0920749A8
Authority
BR
Brazil
Prior art keywords
agonist
antagonist
multialvo
binding proteins
antagonist binding
Prior art date
Application number
BRPI0920749A
Other languages
English (en)
Portuguese (pt)
Inventor
Tan Philip
w blankenship John
Kumar Natarajan Sateesh
Armstrong Thompson Peter
Robert Baum Peter
Original Assignee
Emergent Product Dev Seattle
Aptevo Res & Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Seattle, Aptevo Res & Development Llc filed Critical Emergent Product Dev Seattle
Publication of BRPI0920749A2 publication Critical patent/BRPI0920749A2/pt
Publication of BRPI0920749A8 publication Critical patent/BRPI0920749A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
BRPI0920749A 2008-10-02 2009-10-02 Proteínas de ligação de antagonista multialvo cd86 BRPI0920749A8 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10231908P 2008-10-02 2008-10-02
US10232708P 2008-10-02 2008-10-02
US10233108P 2008-10-02 2008-10-02
US10231508P 2008-10-02 2008-10-02
US10230708P 2008-10-02 2008-10-02
US10233608P 2008-10-02 2008-10-02
US10233408P 2008-10-02 2008-10-02
US10229708P 2008-10-02 2008-10-02
US10228808P 2008-10-02 2008-10-02
PCT/US2009/059446 WO2010040105A2 (en) 2008-10-02 2009-10-02 Cd86 antagonist multi-target binding proteins

Publications (2)

Publication Number Publication Date
BRPI0920749A2 BRPI0920749A2 (pt) 2016-05-03
BRPI0920749A8 true BRPI0920749A8 (pt) 2017-12-12

Family

ID=41557444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920749A BRPI0920749A8 (pt) 2008-10-02 2009-10-02 Proteínas de ligação de antagonista multialvo cd86

Country Status (23)

Country Link
US (2) US9493564B2 (OSRAM)
EP (2) EP3281955A1 (OSRAM)
JP (4) JP5840494B2 (OSRAM)
KR (5) KR20170091801A (OSRAM)
CN (2) CN107056951A (OSRAM)
AU (4) AU2009298131B2 (OSRAM)
BR (1) BRPI0920749A8 (OSRAM)
CA (2) CA3038442A1 (OSRAM)
CY (1) CY1119874T1 (OSRAM)
DK (1) DK2344540T3 (OSRAM)
EA (1) EA024877B1 (OSRAM)
ES (1) ES2657220T3 (OSRAM)
HK (1) HK1251000A1 (OSRAM)
HR (1) HRP20180045T1 (OSRAM)
LT (1) LT2344540T (OSRAM)
MX (1) MX338825B (OSRAM)
NO (1) NO2344540T3 (OSRAM)
NZ (1) NZ592420A (OSRAM)
PL (1) PL2344540T3 (OSRAM)
PT (1) PT2344540T (OSRAM)
SI (1) SI2344540T1 (OSRAM)
WO (1) WO2010040105A2 (OSRAM)
ZA (1) ZA201102637B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
CA2729747A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Il6 immunotherapeutics
US20110152173A1 (en) * 2008-07-02 2011-06-23 Emergent Product Development Seattle ,LLC TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
ES2657220T3 (es) * 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
EA032828B1 (ru) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
JP2013512251A (ja) * 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CA2848656C (en) 2010-09-15 2017-10-10 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
CN101962413B (zh) * 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
CA2833019A1 (en) * 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US20140314712A1 (en) * 2011-11-08 2014-10-23 Umc Utrecht Holding B.V. Fusion protein comprising an interleukin 4 and interleukin
EP2839019A4 (en) 2012-04-20 2016-03-30 Emergent Product Dev Seattle CD3 BINDING POLYPEPTIDES
US9969813B2 (en) 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015085847A1 (zh) 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
JP6202339B2 (ja) * 2013-12-19 2017-09-27 国立研究開発法人国立精神・神経医療研究センター ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN103923934B (zh) * 2014-03-22 2016-11-02 复旦大学 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用
US10624955B2 (en) 2014-05-07 2020-04-21 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP6836500B2 (ja) 2014-05-16 2021-03-03 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 自己免疫状態および炎症状態を治療するための方法および組成物
DK3288965T3 (da) * 2015-04-29 2019-09-23 Mediolanum Farm S P A Opløselig kimær interleukin-10 receptor og terapeutisk anvendelse deraf
KR102749049B1 (ko) 2015-08-07 2025-01-02 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
KR20180054824A (ko) * 2015-09-29 2018-05-24 셀진 코포레이션 Pd-1 결합 단백질 및 이의 사용 방법
SG10201913597VA (en) * 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
US20190338013A1 (en) 2016-02-26 2019-11-07 Imunexus Pty Ltd Multi-Specific Molecules
US10751414B2 (en) * 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
WO2018053401A1 (en) * 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
CN110678482A (zh) * 2017-03-29 2020-01-10 细胞基因公司 包含pd-1结合蛋白的制剂及其制备方法
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
BR112020001180A2 (pt) 2017-07-20 2020-09-08 Aptevo Research And Development Llc proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JPWO2019177053A1 (ja) * 2018-03-13 2021-04-22 国立大学法人北海道大学 全身性エリテマトーデス又は全身性エリテマトーデスに起因して生じる疾患の予防又は治療剤及び膠原病の予防又は治療剤
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
AU2019286396A1 (en) 2018-06-14 2020-12-17 Bioatla, Inc. Multi-specific antibody constructs
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
WO2020047328A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
WO2020097394A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220089679A1 (en) * 2019-01-11 2022-03-24 Fundació Institut D'investigació Biomèdica De Bell Fusion protein with immunosuppressive activity
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
CN114144194B (zh) 2019-04-19 2025-03-14 斯纳凯恩制药私人有限责任公司 一种包含il13的融合蛋白
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US20220306713A1 (en) * 2019-06-10 2022-09-29 Apollomics Inc. (Hangzhou) Antibody-interleukin fusion protein and methods of use
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
CN114302891A (zh) * 2019-07-08 2022-04-08 普罗根有限公司 新的il-10变体蛋白及其用途
CN114867751B (zh) 2019-08-12 2024-11-29 阿帕特夫研究和发展有限公司 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
AU2020402097A1 (en) * 2019-12-13 2022-07-07 Cugene Inc. Novel interleukin-15 (IL-15) fusion proteins and uses thereof
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
US20230303720A1 (en) 2020-01-13 2023-09-28 Aptevo Research And Development Llc Formulations for protein therapeutics
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4157354A4 (en) * 2020-05-27 2024-07-10 Dana-Farber Cancer Institute, Inc. BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
CN117500824A (zh) * 2021-02-01 2024-02-02 奥美药业有限公司 包含IL-10或TGF-β激动剂多肽的嵌合分子
WO2022246244A1 (en) 2021-05-21 2022-11-24 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
WO2024107752A2 (en) * 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024148328A2 (en) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Bispecific pd-l1 and cd40 binding molecules and uses thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6482919B2 (en) 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0665852A1 (en) 1993-07-09 1995-08-09 Amgen Boulder Inc. Recombinant ctla4 polypeptides and methods for making the same
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
PL312718A1 (en) 1993-07-26 1996-05-13 Schering Corp Competitors and opponents of human interleukine-10
JP4137997B2 (ja) 1994-01-11 2008-08-20 ダイアックス コープ． クニッツドメインから誘導されたヒトプラスミンの阻害剤
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5830451A (en) 1996-07-19 1998-11-03 Brigham & Women's Hospital, Inc. Haematopoietic cytokine Epstein Barr virus-induced protein
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE283925T1 (de) * 1996-07-23 2004-12-15 Tanox Pharma B V Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU8800598A (en) 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
CA2317727C (en) 1998-01-23 2013-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
WO1999042077A2 (en) * 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6699972B1 (en) 1999-06-25 2004-03-02 Academia Sinica Chimeric protein and method of controlling tumor growth using the protein
US6613327B1 (en) 1999-07-28 2003-09-02 Genetics Institute, Inc. Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
EP1200592B1 (en) * 1999-07-30 2009-08-26 Schering Corporation Mammalian cytokines; related reagents
US20020071839A1 (en) 2000-03-14 2002-06-13 Mary Collins Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
TWI319405B (en) * 2000-05-26 2010-01-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002228745A1 (en) 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
EP1345969B1 (fr) 2000-12-26 2010-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
CN1911965B (zh) * 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US20050118164A1 (en) 2001-03-09 2005-06-02 William Herman Targeted ligands
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
US20050043516A1 (en) 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US20070148162A1 (en) * 2003-02-27 2007-06-28 Ranjit Bhardwaj Molecule which binds cd80 and cd86
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7307064B2 (en) 2003-08-04 2007-12-11 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
CN1878867A (zh) 2003-11-29 2006-12-13 蔡莹镇 包含用于治疗自身免疫疾病的基因的重组肽载体
AU2005223469A1 (en) 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP1819735A1 (en) 2004-11-04 2007-08-22 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
EP1772465B1 (en) 2005-01-05 2009-02-18 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
SG10201702670VA (en) 2005-06-08 2017-06-29 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
CA2612355A1 (en) 2005-06-16 2006-12-28 Virxsys Corporation Antibody complexes
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
CA2645322A1 (en) 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
NZ612319A (en) 2006-06-12 2015-04-24 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2663536A1 (en) 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
ES2688721T3 (es) 2007-11-01 2018-11-06 Astellas Pharma Inc. Polipéptidos y ácidos nucleicos inmunosupresores
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2321345A1 (en) 2008-07-28 2011-05-18 Emergent Product Development Seattle, LLC Multi-specific binding proteins targeting b cell disorders
CA2736408A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-egfr/anti-igf-1r antibodies
ES2657220T3 (es) * 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EA032828B1 (ru) 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
MX2011011925A (es) 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins

Also Published As

Publication number Publication date
AU2018203491A1 (en) 2018-06-07
PL2344540T3 (pl) 2018-05-30
CA2739460A1 (en) 2010-04-08
US20170015747A1 (en) 2017-01-19
KR20180105731A (ko) 2018-09-28
CA3038442A1 (en) 2010-04-08
JP5840494B2 (ja) 2016-01-06
ZA201102637B (en) 2016-09-28
KR101900953B1 (ko) 2018-09-21
ES2657220T3 (es) 2018-03-02
EP2344540A2 (en) 2011-07-20
JP2016188249A (ja) 2016-11-04
EA024877B1 (ru) 2016-10-31
AU2014203429A1 (en) 2014-07-10
LT2344540T (lt) 2018-03-26
PT2344540T (pt) 2018-02-02
WO2010040105A2 (en) 2010-04-08
CN107056951A (zh) 2017-08-18
BRPI0920749A2 (pt) 2016-05-03
HRP20180045T1 (hr) 2018-03-23
AU2009298131A1 (en) 2010-04-08
JP2014239700A (ja) 2014-12-25
WO2010040105A3 (en) 2010-06-03
AU2009298131B2 (en) 2016-07-14
CN102227447A (zh) 2011-10-26
EA201170443A1 (ru) 2011-12-30
EP3281955A1 (en) 2018-02-14
KR20170091801A (ko) 2017-08-09
NZ592420A (en) 2012-12-21
US9493564B2 (en) 2016-11-15
KR20190064664A (ko) 2019-06-10
MX2011003611A (es) 2011-05-10
DK2344540T3 (da) 2018-01-29
SI2344540T1 (en) 2018-04-30
JP6521915B2 (ja) 2019-05-29
AU2016208322A1 (en) 2016-08-11
KR20110074895A (ko) 2011-07-04
EP2344540B1 (en) 2017-11-29
HK1251000A1 (en) 2019-01-18
US20120100139A1 (en) 2012-04-26
NO2344540T3 (OSRAM) 2018-04-28
JP2019014757A (ja) 2019-01-31
JP2012504425A (ja) 2012-02-23
KR20160120812A (ko) 2016-10-18
CY1119874T1 (el) 2018-06-27
CA2739460C (en) 2019-05-21
MX338825B (es) 2016-05-03

Similar Documents

Publication Publication Date Title
BRPI0920749A8 (pt) Proteínas de ligação de antagonista multialvo cd86
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
MX2013013832A (es) Proteínas de unión receptoras fc.
AR069681A1 (es) Moleculas de union al receptor ox40 humano
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
MX2024007711A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
BR112017016705A2 (pt) agentes de ligação a tnfrsf e uso dos mesmos
CR20180171A (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
MX2017007136A (es) Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
EP3587439A3 (en) Improved quantification of vaccine compositions
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
BR112017011932A8 (pt) Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
NZ590667A (en) Tgf-b antagonist multi-target binding proteins
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
BR112013002695A2 (pt) camundongos que produzem proteínas de ligação compreendendo domínios vl.
BRPI0921320A2 (pt) composições de anticorpo estáveis e métodos para estabilizar os mesmos
UY34343A (es) Proteinas de unión al antígeno cd27l
BR112013011689A2 (pt) compostos e métodos de uso do 4-(selenofeno-2(ou 3)-ilamino) pirimidina substituído

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements